This acquisition consolidates control over a key oncology asset, terminating a previous collaboration and license agreement. This move centralizes commercial and development operations, creating potential needs for system integration and streamlined global GTM strategies.
Filing excerpt
In February 2024, we entered into a purchase agreement with MorphoSys relating to tafasitamab. As a result, we now hold exclusive global rights for tafasitamab, and the collaboration and license agreement was terminated.
What this signalsIntegration work after a deal often opens needs for new systems and services.
Vendors
sec-10kacquisitionCompletedGet every 10-K signal for Incyte and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/67aee1df-bee2-409e-bc38-253f8cd8ff0c returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.
{
"signal_id": "67aee1df-bee2-409e-bc38-253f8cd8ff0c",
"signal_type": "sec-10k",
"signal_subtype": "acquisitionCompleted",
"detected_at": "2026-02-17T06:34:03.067+00:00",
"company": {
"name": "Incyte",
"domain": "incyte.com"
},
"data": {
"detail": "This acquisition consolidates control over a key oncology asset, terminating a previous collaboration and license agreement. This move centralizes commercial and development operations, creating potential needs for system integration and streamlined global GTM strategies.",
"metrics": {
"timeframe": "current_year"
},
"summary": "Incyte acquired exclusive global rights to tafasitamab from MorphoSys in Feb 2024",
"excerpts": "In February 2024, we entered into a purchase agreement with MorphoSys relating to tafasitamab. As a result, we now hold exclusive global rights for tafasitamab, and the collaboration and license agreement was terminated.",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm",
"filing_date": "2026-02-10",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Active integration needs",
"signal_category": "strategic",
"vendors_mentioned": [
"MorphoSys AG"
]
}
}
curl https://signals.autobound.ai/v1/signals/67aee1df-bee2-409e-bc38-253f8cd8ff0c \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.